NCT00699790View on ClinicalTrials.gov

Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Type 2 Diabetes
Interventions
DRUG

CCR2 Antagonist

Tablets, Oral, 50 mg, once daily, 12 weeks

DRUG

Placebo

Tablets, Oral, 0mg, once daily, 12 weeks

Trial Locations (12)

105229

Local Institution, Moscow

117036

Local Institution, Moscow

125315

Local Institution, Moscow

140090

Local Institution, Dzerzhnsky

150023

Local Institution, Yaroslavl

190068

Local Institution, Saint Petersburg

191015

Local Institution, Saint Petersburg

194044

Local Institution, Saint Petersburg

195271

Local Institution, Saint Petersburg

394066

Local Institution, Voronezh

603126

Local Institution, Nizhny Novgorod

625023

Local Institution, Tyumen

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00699790 - Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance | Biotech Hunter | Biotech Hunter